Immunology of Malignant Diseases

  • V. S. Byers
  • R. W. Baldwin

Part of the Immunology and Medicine book series (IMME, volume 6)

Table of contents

  1. Front Matter
    Pages i-xii
  2. R. A. Robins
    Pages 1-20
  3. V. S. Byers
    Pages 55-69
  4. B. M. Vose
    Pages 70-82
  5. N. C. Armitage
    Pages 83-104
  6. F. Vánky, E. Klein, J. Willems, K. Böök, T. Ivert, A. Péterffy
    Pages 105-128
  7. Ph Rümke, J. E. de Vries
    Pages 129-150
  8. S. Paulie, P. Perlmann
    Pages 151-166
  9. A. E. Frankel, C. M. Boyer, R. C. Bast
    Pages 167-224
  10. A. Chachoua, R. Oratz, M. Green, F. M. Muggia
    Pages 225-261
  11. Back Matter
    Pages 262-270

About this book


Over the past 5 years, clinical immunology, as a whole, has advanced more rapidly than over the past 20 years. Many of these advances have been que to monoclonal antibody technology with its ability to identify antigens on tumour cells with a precision never before available. Monoclonal antibodies have the ability to identify subsets of human T-Iymphocytes and aid in diagnosis of both immunodeficiency disorders such as AIDS, or autoimmune diseases, and they can be adapted as drug targeting agents. Additionally, however, major advances have been made in identifying immunomodulating agents, and the last year has seen two such agents, IL-2 and OKT3, made available commercially for such intervention. Furthermore, another immuno­ modulating technique, bone marrow transplantation, ha~ now been established as a curative modality in leukaemia treatment. A central issue in tumour immunology is whether human tumours express antigens which can be termed tumour-specific. This has important implications for both tumour immunity as well as drug targeting. This issue is considered in detail by R. A. Robins in the introductory chapter in which the expression of antigens in human tumours is compared with that in experimentally induced animal tumours. This controversial issue is also considered in later chapters by Bast in breast carcinoma, Riimke and de Vries in melanoma, V{mky in lung cancer, Armitage in colorectal cancer, and Paulie and Perlmann in bladder carcinoma.


blood diseases immunobiology lymphocytes melanoma transplantation tumor

Editors and affiliations

  • V. S. Byers
    • 1
  • R. W. Baldwin
    • 2
  1. 1.Xoma CorporationBerkeleyUSA
  2. 2.Cancer Research Campaign LaboratoriesUniversity of NottinghamNottinghamUK

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media B.V. 1987
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-010-7945-7
  • Online ISBN 978-94-009-3219-7
  • Buy this book on publisher's site